The NCMAG Council makes decisions on the proposed use of cancer medicines.
These medicines uses are planned for review by NCMAG:
NCMAG 126 – Nivolumab plus ipilimumab
For use as neoadjuvant treatment of mismatch repair deficient or microsatellite instability‑high locally advanced colon cancer which is judged to be borderline resectable. (off-label use)
- Council meeting date: 19 March 2026
- Planned publication date: 23 April 2026
NCMAG127 - Arsenic trioxide in combination with all-trans retinoic acid
For treatment of adults with high-risk acute promyelocytic leukaemia (APML). (off-label use and on-patent medicine)
- Council meeting date: 18 June 2026
- Planned publication date: 23 July 2026
NCMAG 128-Pazopanib
For treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy (on-label use and off-patent medicine).
- Council meeting date: 18 June 2026
- Planned publication date: 23 July 2026